Search clinical trials for: Progression on treatment with sunitinib or sorafenib

Total 433902 results

AEterna Zentaris

Completed

Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

Kidney Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

Gastrointestinal Stromal Tumor

United States
Pfizer

Completed

Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting (ADONIS)

Metastatic Renal Cell Carcinoma (mRCC)

Spain, Italy, Belgium, France, United Kingdom, Austria, Greece, Netherlands
Roswell Park Cancer Institute
Novartis

Terminated

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Southwest Oncology Group; Cancer and Leukemia Group...

Completed

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery (ASSURE)

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage II Renal Cell Cancer AJCC v7 | Stage I Renal Cell Cancer AJCC v6 and v7

United States, Canada, Puerto Rico
Bayer

Terminated

A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.

Carcinoma, Renal Cell

Italy, Spain, France, Austria, Poland, United Kingdom, Ireland
AIO-Studien-gGmbH

Terminated

Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer (FOSCO)

Colorectal Neoplasms

Germany
Novartis Pharmaceuticals

Completed

RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib (RECORD-1)

Metastatic Renal Cell Carcinoma

Poland, Canada, France, Italy, Spain, United States, Germany, Australia, Netherlands, Japan
Radboud University Medical Center

Unknown

Temsirolimus-RCC-imaging

Renal Cell Cancer

Netherlands
Fudan University

Terminated

Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer

China
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
Qinghai Red Cross Hospital

Recruiting

Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer

Advanced Cancer | Progression Free Survival | Olanzapine

China
European Organisation for Research and Treatment...
Novartis

Not yet recruiting

177Lu-DOTATATE for Recurrent Meningioma (LUMEN-1)

Recurrent Meningioma
National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
The Second Affiliated Hospital of Kunming Medical...

Not yet recruiting

Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia | Decitabine | Venetoclax | Elderly AML Patients | Unfit, New-diagnosis AML

China
Hoffmann-La Roche

Recruiting

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, Denmark, Spain, Australia, Italy, New Zealand, France, Canada, Germany
Institute of Oncology Ljubljana

Recruiting

Electrochemotherapy for the Treatment of Vulvar Cancer

Vulvar Cancer

Slovenia
European Organisation for Research and Treatment...

Recruiting

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study (LEGATO)

First Progression of Glioblastoma

Netherlands, Austria, Germany
RenJi Hospital
The First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaborators

Recruiting

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

China
Assiut University

Not yet recruiting

Treatment Outcome With Antibiotic Use and Its Resistance Pattern Among Patient With Neonatal Sepsis

Neonatal Sepsis
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Oral Etoposide Combined With Antirotinib and Envollizumab in Elderly Patients With Lung Cancer

Progression Free Survival(PFS)
Philip Morris Products S.A.

Recruiting

Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Smoking | Tobacco Use | COPD

United States, Bulgaria, Czechia, Germany, Japan, Romania, Slovakia, United Kingdom
Fujian Cancer Hospital

Not yet recruiting

the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy

Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology | The TNM (8th) Phase is IV | With EGFR Mutations | Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment | Male or Female | The Age of 18 Years Old or... and other conditions
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8

United States
Zhongnan Hospital

Recruiting

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival

China
Jagiellonian University

Recruiting

Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease (ChIm-NB-PL)

High-Risk Neuroblastoma

Poland
UNICANCER
Seagen Inc.; ARCAGY/ GINECO GROUP

Recruiting

Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer (InTTercePT)

Metastatic Breast Cancer With a Isolated Brain Progression

France
Novartis Pharmaceuticals

Recruiting

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. (EPIK-B5)

Breast Cancer

Germany, Italy, Belgium, Denmark, France, Spain, Finland, Hungary, Ireland, Czechia, Greece, Canada, Portugal, Slovakia, Bulgaria, Poland, Romania
Maria Sklodowska-Curie National Research Institute...
KCRI

Not yet recruiting

Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment (NIVONASO-21)

Nasopharyngeal Cancer

Poland
Telix International Pty Ltd

Not yet recruiting

177Lu-DOTA-rosopatamab With Best Standard of Care (SoC) for the Second Line of Treatment for Metastatic Castrate-resistant Prostate Cancer, Which Expresses PSMA (PROSTACT)

Metastatic Prostate Cancer
Lee's Pharmaceutical Limited

Recruiting

Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Local Progression or Metastatic Melanoma With Failed First-line Treatment

China
Shanghai Chest Hospital

Not yet recruiting

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

NRG1-fused Non-small Cell Lung Cancer

China
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251)

Unresectable Hepatocellular Carcinoma

Canada, France, Korea, Republic of, China, Japan, Spain, Belgium, Croatia, Brazil, Austria, Italy, Costa Rica, Germany, Israel, Thailand, Turkey, Russian Federation, United Kingdom, Taiwan, Philippines, India, Chile, Finland, Greece, Sl... and more
Centre Leon Berard

Recruiting

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune)

Sarcoma

France
RasCal Therapeutics, Inc.

Recruiting

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Glioblastoma | Pancreatic Cancer | Lung Cancer | Colon Cancer | Advanced Malignant Solid Neoplasm | RAS Mutation

United States
Taproot Health

Recruiting

The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)

Melanoma | Sarcoma | Kidney Cancer | Adenocarcinoma | Renal Cell Carcinoma | Cervical Cancer | Acute Myeloid Leukemia | Stomach Cancer | Breast Cancer | Head and Neck Neoplasms | Nasopharyngeal Carcinoma | Glioblastoma | Astrocytoma | Multiple Myeloma | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer and other conditions

United States
Karen-Lise Garm Spindler

Recruiting

IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer (IMPROVE-IT)

Colorectal Cancer | Adjuvant Chemotherapy | Circulating Tumor DNA | Progression Free Survival

Denmark
Xynomic Pharmaceuticals, Inc.

Recruiting

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Renal Cell Carcinoma

China, Spain, United States, Italy, Korea, Republic of, Poland
American Society of Clinical Oncology
Bristol-Myers Squibb; Eli Lilly and Company; Bayer; Merck Sharp & Dohme LLC; Pfizer; AstraZene... and other collaborators

Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Advanced Solid Tumors

United States
Meir Medical Center

Recruiting

A Prospective Study of Clinical Factors Affecting Disease Progression and Treatment Results of Patients With Tumors of the Prostate, Bladder and Kidney.

Kidney Cancer | Prostate Cancer | Bladder Cancer

Israel
Centre Leon Berard
National Cancer Institute, France

Recruiting

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus)

Malignant Solid Neoplasms

France
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
Advanced Accelerator Applications

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2)

Gastro-enteropancreatic Neuroendocrine Tumor

Spain, United States, United Kingdom, France, Canada, Germany, Netherlands, Italy, Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
AstraZeneca

Active, not recruiting

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA)

Hepatocellular Carcinoma

United States, Canada, Brazil, France, Italy, Russian Federation, Spain, Vietnam, Korea, Republic of, China, Germany, Ukraine, Japan, Hong Kong, Taiwan, India, Thailand
Theseus Pharmaceuticals

Terminated

A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Diseases | Neoplasms | Neoplasms, Connective and Soft Tissue | Neoplasms by Histologic Type | Gastrointestinal Neoplasms | Neoplasms, Connective Tissue | Digestive System Neoplasm | Digestive System Disease | Gastrointestinal Stromal Tumors (GIST)

United States
Astellas Pharma Europe Ltd.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone (PRESIDE)

Metastatic Castration Resistant Prostate Cancer

Belgium, France, Spain, Austria, Czechia, Germany, Greece, Italy, Netherlands, Norway, Poland, Russian Federation, Sweden, Switzerland, Turkey, United Kingdom
AtlasMedx, Incorporated

Active, not recruiting

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Homologous Recombination Deficiency | Advanced Malignant Neoplasm

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery (S0931)

Kidney Cancer

United States, Puerto Rico
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Australia, Austria, Belgium, Canada, China, Czechia, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom

Search clinical trials for: Progression on treatment with sunitinib or sorafenib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations